Percutaneous HydroDiscectomy Compared to TESI for Radiculopathy

NCT ID: NCT02414698

Last Updated: 2020-03-02

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-01-31
• Study Completion Date: 2015-03-31

Brief Summary

To compare the outcomes of percutaneous lumbar Hydrodiscectomy (HydroD) with the SpineJet Hydrodiscectomy System to transforaminal epidural steroid injections (TESI) in patients with lumbar radiculopathy due to contained disc herniation with symptoms that persist following a treatment course of conservative management including physical therapy and anti-inflammatory medication.

Detailed Description

Lumbar disc herniation is one of the leading causes of lower back pain and sciatica. If conservative management fails to relieve radiculopathy secondary to lumbar disc herniation, interventional treatments such as epidural steroid injections are indicated. Patients that do not have pain relief from transforaminal epidural steroid injections or over time relief is diminished, surgical intervention is typically recommended and microdiscectomy is the surgical intervention of choice. Over the years, a number of minimally invasive techniques for lumbar disc herniation have been introduced including percutaneous mechanical lumbar discectomy, including percutaneous hydrodiscectomy (HydroD).

The purpose of this study is to compare the outcomes of HydroD with the SpineJet Hydrodiscectomy System to transforaminal epidural steroid injections (TESI) in patients with lumbar radiculopathy due to contained disc herniation that have failed a course of conservative management including anti-inflammatory medication and physical therapy. Patients will be randomized in a 1:1 ratio to Percutaneous Hydrodiscectomy or Transforaminal Epidural Steroid Injections.

Patients randomized to the TESI group that fail to have >50% relief of pain after two courses of TESI injections spaced two weeks apart within 2 months of the procedure, will be provided with the option to cross-over to the HydroD group after which they will follow the same follow-up visits. If after cross-over into the HydroD group they fail to have >50% relief of pain after the initial intervention within 2 months of the procedure, they will be referred for surgery and their participation in the study will end.

Patients randomized to the HydroD group that fail to have >50% relief of pain after the initial procedure, or within 2 months of the procedure, will be provided with the option to cross-over to the TESI group. If after cross-over to the TESI group they fail to have >50% relief of pain after two courses of TESI injections spaced two weeks apart within 2 months of the procedure, they will be referred for surgery and will no longer be followed in the study.

Patients will be followed at 1, and 4, and 2, 6, 12, and 24 months post-procedure. Outcomes assessments include NRS for pain, ODI, neurological and independent physician evaluations.

Conditions

Lumbar Herniated Disc

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Percutaneous Hydrodiscectomy

Percutaneous Hydrodiscectomy with the SpineJet Hydrodiscectomy System

Group Type: ACTIVE_COMPARATOR

Percutaneous Hydrodiscectomy

Intervention Type: PROCEDURE

The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.

TESI

Transforaminal Epidural Steroid Injections

Group Type: ACTIVE_COMPARATOR

TESI

Intervention Type: DRUG

Transforaminal epidural steroid injections given in the lumbar spine.

Interventions

Percutaneous Hydrodiscectomy

The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.

Intervention Type: PROCEDURE

TESI

Transforaminal epidural steroid injections given in the lumbar spine.

Intervention Type: DRUG

Other Intervention Names

Transforaminal epidural steroid injections

Eligibility Criteria

Inclusion Criteria

• Single level subligamentous lumbar disc herniation with a size of up to 1/3 of the spinal canal sagittal diameter, with unilateral radicular pain attributed to nerve root impingement from lumbar disc material correlated with MRI or CT findings
• Axial MRI demonstrating unilateral focal contained disc herniation with single nerve contact
• Patient failed at least 3 weeks of conservative management within a 6 month period including anti-inflammatory medication and physical therapy
• Patient has not had previous epidural steroid injections at the affected lumbar level within 3 months of presenting for the study
• Patient is a candidate for transforaminal epidural steroid injections
• Positive Straight Leg Raising (SLR) test
• Patient has a leg pain > back pain
• The subject is physically and mentally able to participate in the study
• Patient is willing and able to provide informed consent
• Patient is willing and able to comply with the study protocol

Exclusion Criteria

• Patient has had surgery at the affected level
• Extruded or sequestered disc herniation
• Free fragment herniation
• Discogenic pain without nerve root compression
• Previous surgery at the involved lumbar level
• Segmental instability (motion on flexion/extension films)
• Spondylolisthesis > Grade 2
• Severe central canal stenosis or bony impingement at the index level
• Significant loss of disc height (> 60%) compared with the adjacent higher level or disc height < 6mm at affected level
• Motor deficit (strength rating less than 4/5 in the lower extremity test)
• Positive Waddell test (> 3 of 5 tests)
• Active local or systemic infection
• Actively in litigation for pain symptoms
• Currently on Workman's Compensation
• Women who are pregnant

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Montefiore Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sayed E Wahezi, MD

Role: PRINCIPAL_INVESTIGATOR

Montefiore Medical Center

Locations

Montefiore Medical Center

The Bronx, New York, United States

Countries

United States

Other Identifiers

2014-3750

Identifier Type: -

Identifier Source: org_study_id